Afatinib versus gefitinib as first-line treatment of...

  • Main
  • 2016 / 4
  • Afatinib versus gefitinib as first-line treatment of...

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Park, Keunchil, Tan, Eng-Huat, O'Byrne, Ken, Zhang, Li, Boyer, Michael, Mok, Tony, Hirsh, Vera, Yang, James Chih-Hsin, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa, Kim, Dong-
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(16)30033-X
Date:
April, 2016
File:
PDF, 524 KB
english, 2016
Conversion to is in progress
Conversion to is failed